FDA guidance
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for…
FDA guidance · Final · issued Jun 28, 2022
Key facts
| Title | Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Jun 28, 2022 |
| Center | Office of the Commissioner |
| Issuing office | Oncology Center of Excellence, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Topics | Premarket |
| Docket number | FDA-2020-D-1497 |
| Comments close | Dec 1, 2020 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents